北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
作者: Yao, L.1; Liu, Y.2; Li, Z.1; Ouyang, T.1; Li, J.1; Wang, T.1; Fan, Z.1; Fan, T.1; Lin, B.1; Xie, Y.1
关键词: anthracycline ; breast cancer ; HER2 ; neoadjuvant chemotherapy
刊名: ANNALS OF ONCOLOGY
发表日期: 2011-06-01
DOI: 10.1093/annonc/mdq612
卷: 22, 期:6, 页:1326-1331
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: SURGICAL ADJUVANT BREAST ; PREOPERATIVE CHEMOTHERAPY ; SYSTEMIC THERAPY ; RANDOMIZED-TRIALS ; DOXORUBICIN ; WOMEN ; DOCETAXEL ; CYCLOPHOSPHAMIDE ; SENSITIVITY ; EXPRESSION
英文摘要:

Background: The predictive role of human epidermal growth factor receptor 2 (HER2) to adjuvant anthracycline-based chemotherapy remains controversial. Here, we investigated the association between HER2 status and pathological response in breast cancer patients who received neoadjuvant anthracycline-based regimens.

Patients and methods: Women (n = 538) with operable primary breast cancer received neoadjuvant anthracycline-based chemotherapy. Pathological complete response (pCR) was defined as no invasive breast tumor cells in breast after completion of neoadjuvant chemotherapy. HER2 status was determined by immunohistochemistry and/or by fluorescence in situ hybridization in core biopsy breast cancer tissue obtained before initiation of neoadjuvant chemotherapy.

Results: In this cohort of 538 patients, 23.9% of patients achieved a pCR in their breast. HER2-positive tumors had a lower rate of pCR than did HER2-negative tumors (14.7% versus 25.7%, P = 0.013); negative HER2 status remained as an independent favorable predictor of pCR after adjusted for age, estrogen receptor, progesterone receptor, tumor size, chemotherapy cycles, and tumor grade in a multivariate analysis (odds ratio = 3.14; 95% confidence interval = 1.60-6.16, P = 0.001). Furthermore, patients with a pCR had a higher 3-year disease-free survival (DFS) rate than did patients without a pCR (P = 0.007).

Conclusion: Women with HER2-negative breast cancers rather than HER2-positive tumors benefit from anthracycline-based neoadjuvant chemotherapy.

语种: 英语
所属项目编号: 30973436
项目资助者: Program for Breast Cancer Tissue Bank of Beijing ; National Natural Science Foundation of China
WOS记录号: WOS:000291060800012
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/62330
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Canc Hosp, Beijing Canc Hosp & Inst, Breast Ctr, Beijing 100142, Peoples R China
2.Peking Univ, Canc Hosp, Beijing Canc Hosp & Inst,Dept Pathol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China

Recommended Citation:
Yao, L.,Liu, Y.,Li, Z.,et al. HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer[J]. ANNALS OF ONCOLOGY,2011,22(6):1326-1331.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Yao, L.]'s Articles
[Liu, Y.]'s Articles
[Li, Z.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Yao, L.]‘s Articles
[Liu, Y.]‘s Articles
[Li, Z.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace